Published in Lab Business Week, January 30th, 2005
Clolar is the first new leukemia treatment approved specifically for children in more than a decade. Given the unmet need for new treatment options in this seriously ill patient population, Genzyme expects to make Clolar commercially available as quickly as possible in January.
"FDA approval of Clolar is a welcome sign that industry and the agency are beginning to act on the needs of children with cancer very early in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.